骨肉瘤的基因免疫治疗:从溶瘤载体到工程化免疫细胞
Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells.
然而,免疫检查点阻断在未经选择的骨肉瘤患者中疗效有限:在SARC028研究中,22例接受pembrolizumab治疗的骨肉瘤患者中仅观察到1例客观缓解。
ALL SOURCES
Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells.
然而,免疫检查点阻断在未经选择的骨肉瘤患者中疗效有限:在SARC028研究中,22例接受pembrolizumab治疗的骨肉瘤患者中仅观察到1例客观缓解。
CAR-T cell immunotherapy in rhabdomyosarcoma.
通过整合这些进展,合理设计的多模式治疗有望克服耐药机制并改善难治性横纹肌肉瘤的结局,为这种历史上难以治愈的恶性肿瘤带来希望。
Oncolytic virus therapy for osteosarcoma: mechanisms, opportunities, and challenges.
已报道令人鼓舞的临床前证据:VSV-IFN-NIS在犬OS模型中实现了约35%的长期生存率,协同联合方案已显示出超过70%的肿瘤抑制率。
New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.
尽管手术和化疗提高了局限性病例的生存率,但肺转移使生存率显著降低至约20%,凸显了对新型治疗的需求。
Oncolytic Maraba Virus MG1 Mediates Direct and Natural Killer Cell-Dependent Lysis of Ewing Sarcoma.
MG1 能够直接杀死 EWS 细胞并刺激 NK 细胞对该肿瘤的细胞毒性,这表明 MG1 可能为常规治疗疗效目前有限的 EWS 患者提供治疗获益。
Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.
儿童口腔横纹肌肉瘤(RMS)是一种罕见且侵袭性强的头颈部肿瘤,其特征为复杂且以免疫抑制为主的肿瘤免疫微环境。
The paradoxical role of stem cells in osteosarcoma: from pathogenesis to therapeutic breakthroughs.
骨肉瘤(OS)是青少年中最常见的原发性恶性骨肿瘤,具有高转移潜能和治疗耐药性。
Oncolytic Maraba virus MG1 mediates direct and natural killer cell-dependent lysis of Ewing sarcoma.
30 多年来,尤因肉瘤的治疗进展相对有限。
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.
转移性和无应答的儿童骨肉瘤患者预后极差,在过去30年中未见改善。
共 9 条
MEMBER ACCOUNT
登录成功会直接打开下一页。